So far, the effectiveness of anti-IL-5 or anti-IL-5 receptor monoclonal antibodies in severe eosinophilic bronchiectasis has been documented in a case series, which demonstrated marked improvements in exacerbation rates and lung function after six months of treatment (154). This evidence concerns the gene IL5 and eosinophilic bronchiectasis.